On the stock market since 2020, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 50% a year on average.
Sales run at $384.1M a year. A small number, but proof the product has real buyers.
A loss of $41.6M against $384.1M in annual sales.
On our five-subject report card, CLII sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CLII is a high-risk stock — not yet profitable, and its future rides on its product catching on.